Best Mylotarg (Gemtuzumab Ozogamicin) Medicine in India

Mylotarg (Gemtuzumab Ozogamicin) is a targeted anticancer medicine used to treat certain patients with CD33-positive acute myeloid leukemia (AML). It is an antibody-drug conjugate that targets the CD33 protein found on many leukemia cells and delivers a cytotoxic substance directly into these abnormal cells, helping to destroy them and control the growth of leukemia.

Mylotarg is administered by a healthcare professional through an intravenous infusion. The dose and treatment schedule depend on the patient's age, condition, previous treatment, and response to therapy. Patients may receive medicines before the infusion to reduce the risk of infusion-related reactions. Regular blood tests and medical monitoring are required during treatment to check blood cell counts, liver function, and other health parameters.

Common side effects of Mylotarg may include fever, nausea, vomiting, headache, fatigue, bleeding, low blood cell counts, and infusion-related reactions. It can also cause serious liver problems, including veno-occlusive disease (VOD), as well as severe infections and bleeding. Inform your doctor immediately if you develop yellowing of the skin or eyes, abdominal swelling or pain, sudden weight gain, fever, unusual bleeding, difficulty breathing, or other concerning symptoms.

Treatment of CD33-Positive Acute Myeloid Leukemia

Mylotarg (Gemtuzumab Ozogamicin) is used to treat certain patients with CD33-positive acute myeloid leukemia (AML). It targets the CD33 protein found on leukemia cells and delivers a cytotoxic substance directly into these abnormal cells, helping to destroy them. This can reduce the number of leukemia cells and help control the progression of AML.

Some side effects of Mylotarg (Gemtuzumab Ozogamicin) may improve as your body adjusts to the medicine. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Mylotarg (Gemtuzumab Ozogamicin)

Mylotarg (Gemtuzumab Ozogamicin) is administered by a healthcare professional through an intravenous infusion. The dose and treatment schedule depend on the patient's age, condition, previous treatment, and response to therapy. Medicines may be given before the infusion to help reduce the risk of infusion-related reactions. Regular blood tests and medical check-ups are required to monitor blood cell counts, liver function, and treatment response.

Mylotarg is a targeted antibody-drug conjugate that binds to the CD33 protein found on many acute myeloid leukemia (AML) cells. After binding to CD33, the medicine is taken into the leukemia cell and releases a cytotoxic substance called calicheamicin, which damages the cell's DNA. This causes the abnormal leukemia cells to die and helps reduce the number of cancer cells.

• Keep the unopened vial refrigerated between 2°C and 8°C.
• Protect the vial from light by keeping it in the original carton.
• Do not freeze the vial or expose it to freezing temperatures.
• After reconstitution and dilution, store and use the solution within the time and temperature limits specified in the prescribing information.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Mylotarg (Gemtuzumab Ozogamicin).

Pregnancy CONSULT YOUR DOCTOR

Mylotarg may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant. Use effective contraception as advised by your doctor.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment with Mylotarg and for the recommended period after the final dose. Consult your doctor for guidance.

Driving CONSULT YOUR DOCTOR

Mylotarg may cause fatigue, dizziness, or other effects that can affect your ability to drive safely. Avoid driving if these symptoms occur.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment. Your doctor may recommend appropriate monitoring.

Liver CAUTION

Tell your doctor if you have liver problems. Mylotarg can cause serious liver problems, including veno-occlusive disease, so liver function may be monitored regularly during treatment.

• Attend all scheduled Mylotarg (Gemtuzumab Ozogamicin) infusions and follow your doctor's treatment schedule carefully.
• Attend regular blood tests to monitor blood cell counts, liver function, and your overall health during treatment.
• Inform your doctor immediately if you develop fever, chills, unusual bleeding, or other signs of infection.
• Contact your doctor promptly if you notice yellowing of the skin or eyes, dark urine, abdominal swelling or pain, or sudden weight gain.
• Inform your healthcare team about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
• Read More About - Mylotarg (Gemtuzumab Ozogamicin) from Pharma Five.

Pharma Five, may facilitate the import of Mylotarg (Gemtuzumab Ozogamicin) in small quantities for personal medical use. For this purpose, the applicant must submit an application in Form 12A along with a prescription from a Registered Medical Practitioner (RMP).

Pharma Five offers professional pharmaceutical facilitation to patients seeking Mylotarg (Gemtuzumab Ozogamicin), supporting access to specialized medicines through the required import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.